Literature DB >> 8567830

Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach.

R S Rai1, L Regan, K Clifford, W Pickering, M Dave, I Mackie, T McNally, H Cohen.   

Abstract

Five hundred consecutive women (median age 33 years; range 19-45) with a history of recurrent miscarriage (median 4; range 3-16) were screened for the presence of antiphospholipid antibodies (APA)-lupus anticoagulant (LA) and/or anticardiolipin antibodies (ACA). The prevalence of persistently positive tests for LA was 9.6% and for immunoglobulin G (IgG) and immunoglobulin M (IgM) ACA was 3.3 and 2.2% respectively. Only seven women (1.4%) were LA and ACA positive. Repeat testing, after an interval of at least 8 weeks, demonstrated that only 65.7% of LA positive, 36.6% IgG ACA positive and 36.0% IgM ACA positive women on initial testing had a second positive test result. The dilute Russell's viper venom time detected the LA significantly more often than either the activated partial thromboplastin time or the kaolin clotting time (P < 0.001). There was no difference in the gestation of previous miscarriages between APA positive and APA negative women. There was no difference in the plasma beta 2-glycoprotein-I concentrations between APA positive and APA negative women with miscarriages and normal women. All women with a history of recurrent miscarriage should be tested for the presence of both LA and ACA. A second confirmatory test should be performed in those with an initial positive test result.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8567830     DOI: 10.1093/oxfordjournals.humrep.a136224

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  25 in total

1.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

Review 2.  Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia.

Authors:  Paulien G de Jong; Stef Kaandorp; Marcello Di Nisio; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2014-07-04

Review 3.  Low molecular weight heparin in immunological recurrent abortion--the incredible cure.

Authors:  Gautam N Allahbadia; Swati G Allahbadia
Journal:  J Assist Reprod Genet       Date:  2003-02       Impact factor: 3.412

4.  Characteristics of pregnancy complications and treatment in obstetric antiphospholipid syndrome in China.

Authors:  Zhuochao Zhou; Jialin Teng; Yue Sun; Honglei Liu; Xiaobing Cheng; Yutong Su; Chengde Yang; Junna Ye
Journal:  Clin Rheumatol       Date:  2019-07-09       Impact factor: 2.980

5.  Antiphospholipid Syndrome during pregnancy: the state of the art.

Authors:  Fosca A F Di Prima; Oriana Valenti; Entela Hyseni; Elsa Giorgio; Marianna Faraci; Eliana Renda; Roberta De Domenico; Santo Monte
Journal:  J Prenat Med       Date:  2011-04

Review 6.  Anticoagulant therapy and pregnancy.

Authors:  Aiko Makino; Mayumi Sugiura-Ogasawara
Journal:  Reprod Med Biol       Date:  2008-02-01

Review 7.  Recurrent miscarriage.

Authors:  Kirsten Duckitt; Aysha Qureshi
Journal:  BMJ Clin Evid       Date:  2011-02-01

Review 8.  Thrombophilia in pregnancy.

Authors:  I D Walker
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

9.  Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway.

Authors:  Melissa J Mulla; Jan J Brosens; Larry W Chamley; Ian Giles; Charis Pericleous; Anisur Rahman; Shawna K Joyce; Britta Panda; Michael J Paidas; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2009-08       Impact factor: 3.886

Review 10.  Recurrent miscarriage.

Authors:  Kirsten Duckitt; Aysha Qureshi
Journal:  BMJ Clin Evid       Date:  2008-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.